INTRODUCTION AND OBJECTIVES: Agent Orange (AO), a defoliant used during the Vietnam War, contained the carcinogen dioxin. AO exposure is associated with earlier age of prostate cancer (PCa) diagnosis, as well as increased risk of high-grade and metastatic disease; however, little evidence exists demonstrating worse cancer outcomes. Given the paucity of data assessing the impact of AO exposure on PCa outcomes, we conducted a large observational study evaluating the impact of AO on PCa survival in Veterans Affairs (VA) patients treated with androgen deprivation therapy (ADT). This study is of particular importance because Vietnam Veterans are approaching the average age of PCa diagnosis.
METHODS: We retrospectively examined the association between AO exposure in men with PCa being treated with ADT in national VA databases. Patients were diagnosed with PCa from 2000-2008 with follow-up through May 2016. Clinical, pathologic and demographic variables were compared by AO exposure. Associations between AO and overall survival (OS), skeletal related events (SRE), and cancer specific survival (CSS) were performed using adjusted Cox proportional hazard models before and after inverse propensity score weighted (IPSW) adjustment. A propensity score was computed by multinomial logistic regression with a single-level outcome variable (AO exposure) with predictor variables: age at ADT initiation, race, Charlson Comorbitiy Indices (CCI), year of diagnosis, PSA at diagnosis, Gleason score, docetaxel use, and local therapy. IPSW was utilized to minimize confounding variables inherent in retrospective non-randomized observational studies.
RESULTS: Overall, 87,344 patients were identified. AO exposed (n[3,475) were younger (p<0.001), had lower PSAs (p[0.002), and more likely to receive both local therapy and chemotherapy (p<0.001) compared to non-exposed (n[83,869) CONCLUSIONS: Agent Orange exposure was associated with decreased risk of death in men receiving ADT for advanced PCa and does not appear to be associated with worse oncologic outcomes.
Source of Funding: Department of Defense Prostate Cancer Research Program (PC150221)
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Kerri Beckmann*, Beth Russell, Debra Josephs, Hans Garmo, London, United Kingdom; Christel Haggstrom, Umea, Sweden; Lars Holmberg, London, United Kingdom; Par Stattin, Uppsala, Sweden; Mieke Van Hemelrijck, London, United Kingdom; Jan Adolfsson, Stockholm, Sweden INTRODUCTION AND OBJECTIVES: Chronic inflammation has been postulated to play a role in cancer aetiology but evidence in the case of prostate cancer (PCa) is unclear. The objective of this study was to determine whether a history of chronic inflammatory diseases (CIDs) or exposure to anti-inflammatory medications (AIMs) is associated with risk of PCa.
METHODS: A case-control design was used: 55,937 cases (all men diagnosed with prostate cancer between 2007-2012) and 279,618 age-matched population controls were selected from the Prostate Cancer Database Sweden (PCBaSe). History of CIDs and AIMs were determined through linkage with national patient and drug registers. Conditional logistic regression was used to investigate associations with any exposure, and for specific disease and medication subtypes, and additionally, according to exposure time/dose. RESULTS:: Odds of PCa diagnosis were increased slightly among men with prior history of any CIDs (OR: 1.08; 95%CI: 1.04-1.12). No association was seen for advanced PCa (high risk/ non-localised), except specifically for prostatitis. For most CIDs subtypes, odds were elevated when first presenting with CIDs during the previous 12 months. The only subtype showing elevated odds for >5 years exposure was allergies/asthma (OR: 1.21; 95%CI: 1.04-1.40). Odds were increased among men with any AIMS exposure (OR: 1.26; 95%CI: 1.24-1.29) and
